Prevnar

Prevnar®

Pediatrics A proprietary 7-valent conjugate vaccine for routine immunization against invasive pneumococcal disease in infants

Prevnar

(prĕv′năr)
Pneumococcal seven-valent conjugate vaccine
Mentioned in ?
References in periodicals archive ?
Apart from male libido drug Viagra and cholesterol drug Lipitor, Pfizer's major drugs include nerve pain treatment Lyrica and Prevnar, a treatment for pneumonia.
US Pharmaceutical producer Pfizer and the Biovac Institute (Biovac) inked a $20m technology transfer deal for local production of Pfizer s vaccine Prevnar 13, that secures children from many pneumonia and associated infections.
The board includes Professor Alf Lindberg, former secretary of the Nobel Committee, Head of R&D at Wyeth Vaccines, EVP of R&D at Sanofi Pasteur and lead developer of Prevnar, Prof.
the world's second-largest drug company in terms of revenue, makes drugs including the pain and arthritis treatment Celebrex, Prevnar pneumococcal vaccines, and fibromyalgia treatment Lyrica.
31 billion after recent approval of Prevnar 13, which blocks more strains of the bacteria.
The other is pneumococcal conjugate vaccine, PCV13 (brand name Prevnar 13), which is routinely given to infants and toddlers, but was approved by the FDA in 2011 for use in adults 50 and older.
Doctors Immediate Care provide vaccines for Hep B, HIB, DTaP, IPV, Prevnar, Rotatek, CBC and lead level, MMR, Varicella, Meningococcal, HPV #1, HPV #2, HPV #3, Gardasil, Zoster (Shingles).
She used the example of Prevnar 13, manufactured exclusively by Pfizer, which prevents ear infections, pneumonia and other diseases in children.
The company's top two sellers are now Lyrica, which treats nerve and muscle pain, and the Prevnar line of vaccines.
Summary: Kathrin Jansen is a microbiologist with at least two breakthrough vaccines to her name: she brought the cervical cancer vaccine Gardasil to market for Merck and helped develop the $4 billion a year pneumonia and meningitis vaccine Prevnar 13 for Pfizer.
NYSE:PFE) presented today the results from a Phase 3 study demonstrating the immunogenicity, tolerability and safety of Prevnar 13[R] (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein])in adults infected with human immunodeficiency virus (HIV).
Prevnar 13 is licensed for the prevention of IPD in children aged 6 weeks through 5 years, and for the prevention of both IPD and pneumococcal pneumonia in adults aged 50 years and older.